GE HealthCare Technologies Inc. Common Stock

GE HealthCare Technologies Inc. Common Stock

Compare this stock

GEHC Stock Report Card

$

VolatilityTechnicalsProfitPerformanceEarningsDividendAnalyst Price Targets

54%

Performance

Score:

100/100

GEHC returned 33.40% in the last 12 months. Based on SPY's performance of 13.09%, its performance is above average giving it a score of 100 of 100.

Analyst Price Targets

Score:

10/100

1 analysts offer 12-month price targets for GEHC. Together, they have an average target of 0, the most optimistic target put GEHC at 0 within 12-months and the most pessimistic has GEHC at 0.

Technicals

Score:

75/100

GEHC receives a 75 of 100 based on 14 indicators. 10 are bullish, 3 are bearish.

Earnings

Score:

100/100

GEHC has missed earnings 0 times in the last 20 quarters.

Profit

Score:

51/100

Out of the last 8 quarters, GEHC has had 8 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

Score:

59/100

GEHC has had a higher than average amount of volatility over the last 12 months giving it a score of 58 of 100.

Dividend

Score:

10/100

GEHC's most recent dividend was $0.03 per share, based on a share price of $72.21. It was a payout ratio of 3.35% compared to their total earnings.

GE HealthCare Technologies Inc. Common Stock Summary

Nasdaq / GEHC
Healthcare
Healthcare - Information Services
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, Hong Kong, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, and X-ray systems, as well as women's health products. The Ultrasound segment provides screening, diagnosis, treatment, and monitoring of certain diseases through radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment involved in the provision of medical devices, consumable products, services, and digital solutions through patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal infant care products. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals, administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents, or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes that are injected into a patient prior to a diagnostic imaging scan. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.